388 related articles for article (PubMed ID: 19802994)
1. The in-vivo antibacterial activity of ceftazidime (Gr 20263)--a comparison with other new beta-lactam antibiotics and gentamicin.
Acred P; Ryan DM; Sowa MA; Watts CM
J Antimicrob Chemother; 1981 Sep; 8 Suppl B():247-55. PubMed ID: 19802994
[TBL] [Abstract][Full Text] [Related]
2. In-vitro comparison of ceftazidime and nine other antimicrobial agents against hospital strains of Gram-negative bacteria.
Wilkinson LD; Gentry LO
J Antimicrob Chemother; 1981 Sep; 8 Suppl B():53-6. PubMed ID: 19802969
[TBL] [Abstract][Full Text] [Related]
3. Aminoglycosides plus beta-lactams against gram-negative organisms. Evaluation of in vitro synergy and chemical interactions.
Giamarellou H
Am J Med; 1986 Jun; 80(6B):126-37. PubMed ID: 3088998
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo antibacterial activities of FK037, a new parenteral cephalosporin.
Nishino T; Otsuki M; Hatano K; Nishihara Y
Chemotherapy; 1994; 40(3):167-82. PubMed ID: 8205935
[TBL] [Abstract][Full Text] [Related]
5. In-vitro activity of ceftazidime, a beta-lactamase stable cephalosporin.
Neu HC
J Antimicrob Chemother; 1981 Sep; 8 Suppl B():131-4. PubMed ID: 19810175
[TBL] [Abstract][Full Text] [Related]
6. Susceptibility of gentamicin sensitive and resistant gram negative bacilli to ceftazidime.
Bremner DA
Pathology; 1987 Jul; 19(3):274-6. PubMed ID: 3124067
[TBL] [Abstract][Full Text] [Related]
7. In-vitro studies with ceftazidime against aerobic gram-negative bacilli and Bacteroides fragilis group.
Acuna G; Johnston J; Young LS; Martin WJ
J Antimicrob Chemother; 1981 Sep; 8 Suppl B():83-9. PubMed ID: 19810170
[TBL] [Abstract][Full Text] [Related]
8. Ceftazidime, a pseudomonas-active cephalosporin: in-vitro antimicrobial activity evaluation including recommendations for disc diffusion susceptibility tests.
Jones RN; Barry AL; Thornsberry C; Gerlach EH; Fuchs PC; Gavan TL; Sommers HM
J Antimicrob Chemother; 1981 Sep; 8 Suppl B():187-211. PubMed ID: 19802985
[TBL] [Abstract][Full Text] [Related]
9. Activities of new beta-lactam antibiotics against isolates of Pseudomonas aeruginosa from patients with cystic fibrosis.
Prince AS; Neu HC
Antimicrob Agents Chemother; 1981 Oct; 20(4):545-6. PubMed ID: 6282199
[TBL] [Abstract][Full Text] [Related]
10. An in-vitro comparison of new cephalosporins with special reference to Pseudomonas aeruginosa.
van Klingeren B
J Antimicrob Chemother; 1981 Sep; 8 Suppl B():97-105. PubMed ID: 19810171
[TBL] [Abstract][Full Text] [Related]
11. Antibacterial activity of N-formimidoyl thienamycin in comparison with cefotaxime, lamoxactam, cefoperazone, piperacillin gentamicin.
Braveny I; Machka K; Elsser R
Infection; 1982 Jan; 10(1):45-9. PubMed ID: 6279523
[TBL] [Abstract][Full Text] [Related]
12. [In vitro activity of cefmenoxime (SCE 1365) against 616 hospital strains of gram-negative bacilli chosen for beta-lactam resistance. Comparison with cefotaxime, lamoxactam and ceftazidime].
Le Noc P; Bryskier A; Le Noc D
Pathol Biol (Paris); 1983 May; 31(5):351-6. PubMed ID: 6312396
[TBL] [Abstract][Full Text] [Related]
13. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
Jones RN; Sader HS; Fritsche TR; Pottumarthy S
Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of antimicrobial susceptibility for beta-lactams using the Etest method against clinical isolates from 100 medical centers in Japan (2006).
Ishii Y; Tateda K; Yamaguchi K;
Diagn Microbiol Infect Dis; 2008 Feb; 60(2):177-83. PubMed ID: 17931820
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of moxalactam against pathogenic bacteria and its comparison with other antibiotics.
Perrymann F; Flournoy DJ; Qadri SM
Chemotherapy; 1983; 29(1):37-42. PubMed ID: 6219865
[TBL] [Abstract][Full Text] [Related]
16. The in-vitro activity of ceftazidime against clinically important pathogens.
Knothe H; Dette GA
J Antimicrob Chemother; 1981 Sep; 8 Suppl B():33-41. PubMed ID: 19810167
[TBL] [Abstract][Full Text] [Related]
17. Ceftazidime: comparative in-vitro study.
Verbist L; Verhaegen J
J Antimicrob Chemother; 1981 Sep; 8 Suppl B():67-71. PubMed ID: 19802971
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the in vitro and in vivo antibacterial activities of cefepime (BMY-28142) with ceftazidime, cefuzonam, cefotaxime and cefmenoxime.
Masuyoshi S; Hiraoka M; Inoue M; Tomatsu K; Hirano M; Mitsuhashi S
Drugs Exp Clin Res; 1989; 15(1):1-10. PubMed ID: 2663406
[TBL] [Abstract][Full Text] [Related]
19. Comparative activities of the oxa-beta-lactam LY127935, cefotaxime, cefoperazone, cefamandole, and ticarcillin against multiply resistant gram-negative bacilli.
Hall WH; Opfer BJ; Gerding DN
Antimicrob Agents Chemother; 1980 Feb; 17(2):273-9. PubMed ID: 6247970
[TBL] [Abstract][Full Text] [Related]
20. The in-vitro activity of ceftazidime: comparison with other beta-lactam antibiotics.
Vanhoof R; Gordts B; Coignau H; Stas G; Butzler JP
J Antimicrob Chemother; 1981 Sep; 8 Suppl B():63-6. PubMed ID: 19802970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
